Suppression of hepatic glucose production

Suppression of hepatic glucose production refers to the reduction in the rate at which the liver produces glucose, predominantly through inhibition of gluconeogenesis and glycogenolysis. This process is a major therapeutic goal in type 2 diabetes and is achieved through cellular and hormonal signaling pathways that modulate key enzymes such as phosphoenolpyruvate carboxykinase (PEPCK), glucose-6-phosphatase (G6Pase), and pyruvate carboxylase. Drugs like metformin and insulin exert their glucose-lowering efficacy largely through this mechanism by modulating gene expression, enzyme activity, and substrate availability for hepatic glucose production[2][3][5][9]. Various signaling pathways, including insulin/AKT, AMPK, and glucagon signaling, play central roles in this regulation[2][5][6][9]. Suppression of hepatic glucose production is a mechanistic pathway/process rather than a molecular target. It involves multiple targets (receptors, enzymes, signaling proteins) but cannot be mapped to a single entity for canonical target data structure purposes. If structured information is required on therapeutic targets involved in hepatic glucose production suppression, consider individual enzymes or receptors (e.g., insulin receptor, glucokinase, AMPK, PEPCK, G6Pase, GLP-1 receptor) rather than this general process[2][3][6][9].

Other names

suppression of hepatic gluconeogenesisinhibition of hepatic glucose outputinhibition of hepatic gluconeogenesis

Inhibition of gluconeogenic enzyme expression (e.g., PEPCK, G6Pase), Activation of insulin signaling, Activation of AMPK pathway, Suppression of adipose lipolysis leading to reduced substrate availability for gluconeogenesis, Suppression of glucagon secretion